Welcome to our dedicated page for Scholar Rock Holding Corporation news (Ticker: $SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scholar Rock Holding Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scholar Rock Holding Corporation's position in the market.
Rhea-AI Summary
Scholar Rock (SRRK) provided corporate updates and highlighted upcoming priorities for 2024, including advancing their industry-leading antimyostatin pipeline to treat spinal muscular atrophy and cardiometabolic disorders. They reported year-end cash and cash equivalents of approximately $280 million and announced plans to present at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
-
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) to present at J.P. Morgan 42nd Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
-
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 78,576 shares of its common stock to 6 newly hired employees. The awards include stock options to purchase 44,900 shares and restricted stock units (RSUs) for 33,676 shares. The options have an exercise price of $18.07 and will vest over time. The awards are subject to the 2022 Inducement Equity Plan and the company's board of directors' approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) Grants Inducement Equity Awards to Newly Hired Employee - Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company, has announced the granting of inducement equity awards to a newly hired employee. The awards include stock options and restricted stock units, subject to the terms and conditions of the 2022 Inducement Equity Plan. The options have an exercise price of $9.88, vesting over time, while the RSUs will vest in four equal annual installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) reported completing enrollment for the pivotal Phase 3 SAPPHIRE trial evaluating apitegromab, with topline data expected in 4Q 2024. They also announced expansion into cardiometabolic disorders with SRK-439 and presented new data supporting proof of concept for SRK-181. Additionally, they completed a $98 million public offering, extending projected cash runway into the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
Scholar Rock announces promising anti-tumor activity in patients with clear cell renal cell carcinoma (ccRCC) in its Phase 1 DRAGON trial of SRK-181. The objective response rate (ORR) was 21.4% and the disease control rate (DCR) was 57%. Biomarker data supports proof of mechanism across multiple tumor types. Safety data shows SRK-181 is generally well tolerated. The company will discuss the SRK-181 program during a conference call on November 7th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Scholar Rock, a clinical-stage biopharmaceutical company, will participate in upcoming investor conferences: Truist Securities BioPharma Symposium on November 9, 2023, and Piper Sandler 35th Annual Healthcare Conference on November 28, 2023. A live webcast of the Piper Sandler event will be available on the Scholar Rock website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary
Scholar Rock to host conference call to discuss Q3 2023 financial results and business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
-
Rhea-AI Summary
Scholar Rock to present data from the DRAGON trial at the Society for Immunotherapy of Cancer Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
Rhea-AI Summary
Scholar Rock announces the closing of its underwritten public offering, raising approximately $97.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
Scholar Rock Holding Corporation
Nasdaq:SRRK
SRRK Rankings
SRRK Stock Data
1.20B
48.17M
2.25%
106.94%
16.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
CAMBRIDGE
About SRRK
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s